DRREDDY

Fundamental Drivers Bullish/Supportive Factors Steady revenue growth: Strong topline performance even when profit dips; Q3 revenue was +4 % YoY. Undervalued vs peers: Lower P/E than many pharma sector peers, making it potentially attractive for value investors. Global footprint: Exposure to India, US, Europe and emerging markets can cushion region-specific headwinds. Challenges/Headwinds Profit compression: Recent Q3 profits fell 14 % YoY, partly due to product-specific issues in the US. US business pressure: Analyst previews warned of expected profit declines driven by North America pricing/volume challenges. Mixed analyst views: Some brokerages maintain Buy ratings with targets above current levels, while others are Hold or Sell with lower targets.